American Research & Management Company’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $2.7M | Hold |
9,312
| – | – | 0.74% | 39 |
|
|
2022
Q2 | $2.62M | Sell |
9,312
-218
| -2% | -$58.3K | 0.67% | 46 |
|
|
2022
Q1 | $2.49M | Buy |
9,530
+20
| +0.2% | +$4.75K | 0.55% | 53 |
|
|
2021
Q4 | $2.09M | Buy |
9,510
+75
| +0.8% | +$14.6K | 0.45% | 55 |
|
|
2021
Q3 | $1.71M | Buy |
9,435
+60
| +0.6% | +$11.7K | 0.4% | 57 |
|
|
2021
Q2 | $1.89M | Sell |
9,375
-500
| -5% | -$105K | 0.43% | 55 |
|
|
2021
Q1 | $2.12M | Sell |
9,875
-13
| -0.1% | -$2.85K | 0.51% | 50 |
|
|
2020
Q4 | $2.34M | Buy |
+9,888
| New | +$2.27M | 0.61% | 46 |
|
|
2020
Q3 | – | Sell |
-9,888
| Closed | -$2.87M | – | 377 |
|
|
2020
Q2 | $2.87M | Buy |
9,888
+13
| +0.1% | +$3.52K | 0.87% | 36 |
|
|
2020
Q1 | $2.35M | Sell |
9,875
-525
| -5% | -$120K | 0.89% | 35 |
|
|
2019
Q4 | $2.28M | Hold |
10,400
| – | – | 0.67% | 43 |
|
|
2019
Q3 | $1.76M | Sell |
10,400
-600
| -5% | -$106K | 0.53% | 50 |
|
|
2019
Q2 | $2.02M | Sell |
11,000
-200
| -2% | -$35K | 0.6% | 48 |
|
|
2019
Q1 | $2.06M | Hold |
11,200
| – | – | 0.59% | 44 |
|
|
2018
Q4 | $1.86M | Hold |
11,200
| – | – | 0.63% | 46 |
|
|
2018
Q3 | $2.16M | Buy |
11,200
+100
| +0.9% | +$17.8K | 0.64% | 46 |
|
|
2018
Q2 | $1.89M | Buy |
11,100
+2,000
| +22% | +$310K | 0.66% | 42 |
|
|
2018
Q1 | $1.48M | Buy |
9,100
+200
| +2% | +$32.7K | 0.49% | 49 |
|
|
2017
Q4 | $1.33M | Sell |
8,900
-50
| -0.6% | -$7.4K | 0.41% | 56 |
|
|
2017
Q3 | $1.36M | Hold |
8,950
| – | – | 0.44% | 56 |
|
|
2017
Q2 | $1.15M | Hold |
8,950
| – | – | 0.38% | 60 |
|
|
2017
Q1 | $979K | Sell |
8,950
-75
| -0.8% | -$6.6K | 0.35% | 56 |
|
|
2016
Q4 | $665K | Sell |
9,025
-600
| -6% | -$48.8K | 0.23% | 73 |
|
|
2016
Q3 | $839K | Sell |
9,625
-175
| -2% | -$16.5K | 0.31% | 66 |
|
|
2016
Q2 | $843K | Buy |
9,800
+200
| +2% | +$17.3K | 0.32% | 63 |
|
|
2016
Q1 | $763K | Buy |
9,600
+200
| +2% | +$18.1K | 0.32% | 67 |
|
|
2015
Q4 | $1.18M | Buy |
9,400
+350
| +4% | +$42.3K | 0.51% | 56 |
|
|
2015
Q3 | $942K | Buy |
9,050
+100
| +1% | +$12.8K | 0.41% | 62 |
|
|
2015
Q2 | $1.1M | Buy |
8,950
+450
| +5% | +$56.7K | 0.45% | 60 |
|
|
2015
Q1 | $1M | Hold |
8,500
| – | – | 0.41% | 61 |
|
|
2014
Q4 | $1.01M | Hold |
8,500
| – | – | 0.37% | 64 |
|
|
2014
Q3 | $955K | Hold |
8,500
| – | – | 0.34% | 65 |
|
|
2014
Q2 | $805K | Hold |
8,500
| – | – | 0.28% | 71 |
|
|
2014
Q1 | $601K | Hold |
8,500
| – | – | 0.21% | 81 |
|
|
2013
Q4 | $632K | Hold |
8,500
| – | – | 0.23% | 77 |
|
|
2013
Q3 | $644K | Sell |
8,500
-500
| -6% | -$39.8K | 0.26% | 77 |
|
|
2013
Q2 | $721K | Buy |
+9,000
| New | +$663K | 0.29% | 74 |
|
Other funds holding VRTX
American Research & Management Company's VRTX Position: Q3 2022 in Review
American Research & Management Company held its Vertex Pharmaceuticals (VRTX) position steady in Q3 2022 at 9,312 shares worth $2.7M. The position accounts for 0.74% of the portfolio, ranked #39.
American Research & Management Company first reported a position in VRTX in Q2 2013 and has held it in 37 quarters since. The position peaked at $2.87M in Q2 2020. 1,125 funds tracked by Wall St. Rank hold VRTX as of Q3 2022.
- American Research & Management Company held 9,312 shares of Vertex Pharmaceuticals worth $2.7M as of Q3 2022.
- American Research & Management Company left its Vertex Pharmaceuticals share count unchanged in Q3 2022.
- Vertex Pharmaceuticals made up 0.74% of American Research & Management Company's portfolio in Q3 2022, its #39 holding.
- American Research & Management Company first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 37 quarters since.
- American Research & Management Company's Vertex Pharmaceuticals position peaked at $2.87M in Q2 2020.
- 1,125 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2022.
Based on American Research & Management Company's 13F filing for Q3 2022, filed 7 Oct 2022.